Small Cell Lung Cancer
Conditions
Brief summary
Quantitative measurements of 68Ga-EVG321 radioactivity in volumes of interest (VOIs) from whole-body images over target organs will be made at several time points
Detailed description
Safety and tolerability, including treatment emergent adverse events and pre/post-68Ga-EVG321 PET/CT lab values, ECGs and vital signs, Pharmacokinetic parameters [e.g., Cmax, area under the curve (AUC), total clearance (CL), steady-state volume of distribution (Vss) and mean residence time (MRT)] of 68Ga- EVG321 in both healthy tissues and primary/metastatic lesions, Comparison of 68Ga-EVG321 PET/CT imaging to determine the presence of CCK2R expressing SCLC relative to histopathology
Interventions
None listed
Sponsors
Evergreen Theragnostics Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantitative measurements of 68Ga-EVG321 radioactivity in volumes of interest (VOIs) from whole-body images over target organs will be made at several time points | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety and tolerability, including treatment emergent adverse events and pre/post-68Ga-EVG321 PET/CT lab values, ECGs and vital signs, Pharmacokinetic parameters [e.g., Cmax, area under the curve (AUC), total clearance (CL), steady-state volume of distribution (Vss) and mean residence time (MRT)] of 68Ga- EVG321 in both healthy tissues and primary/metastatic lesions, Comparison of 68Ga-EVG321 PET/CT imaging to determine the presence of CCK2R expressing SCLC relative to histopathology | — |
Countries
Austria, Germany, Italy
Outcome results
None listed